Anti VEGF-TKI Treatment and New Renal Adverse Events Not Reported in Phase III Trials

In conclusion, these 2 c ases argue for increased awareness for the possibility of renal failure as a consequence of anti-VEFG treatment. Predisposing conditions like known mild chronic renal insufficiency with only mild proteinuria and with atherosclerosis or precipitating co-medications like zoledronate infusion need to b e accounted for to prevent these severe AEs.Eur Thyroid J
Source: European Thyroid Journal - Category: Endocrinology Source Type: research